Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

174.80
Delayed Data
As of Sep 23
 -0.82 / -0.47%
Today’s Change
130.09
Today|||52-Week Range
176.85
+7.68%
Year-to-Date
Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?
Sep 23 / TheStreet.com - Paid Partner Content
Stock Market News for September 15, 2016
Sep 15 / Zacks.com - Paid Partner Content
New Setback for Sanofi's Lantus Increases Need for M&A
Sep 22 / TheStreet.com - Paid Partner Content
Takeda earmarks $15bn for US pharma acquisitions
Sep 13 / FT.com - Paid Partner Content
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Sep 21 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Spectrum Pharmaceuticals, Amgen, AbbVie and Vertex...
Sep 13 / Zacks.com - Paid Partner Content
Stock Market News for September 21, 2016
Sep 21 / Zacks.com - Paid Partner Content
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Sep 13 / Zacks.com - Paid Partner Content
Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
Sep 19 / Zacks.com - Paid Partner Content
3 Drug Stocks That Could Benefit from Key FDA Events in Sep 2016
Sep 12 / Zacks.com - Paid Partner Content
Is This New Market the Biggest Investment Idea of the Decade?
Sep 17 / MotleyFool.com - Paid Partner Content
Two Things You Must Understand About Biotech Investing
Sep 11 / MotleyFool.com - Paid Partner Content
Novartis Reports Positive Phase II Data on Migraine Drug
Sep 16 / Zacks.com - Paid Partner Content